title: Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization.
abstract: OBJECTIVE
  To assess the impact of elevated peak serum E(2) levels (EPE(2); defined as levels >90th percentile) on the day of hCG administration during controlled ovarian hyperstimulation (COH) for IVF on the likelihood for small for gestational age (SGA), preeclampsia (PreE), and preterm delivery (PTD) in singleton pregnancies.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Tertiary-care academic medical center.
  
  
  METHODS
  Singleton live-birth pregnancies conceived after fresh IVF-ET.
  
  
  METHODS
  None.
  
  
  METHODS
  The delivery rate of SGA infants and the development of PreE and PTD in patients with and without EPE(2).
  
  
  RESULTS
  Patients with EPE(2) during COH were more likely to deliver SGA infants (7 [26.9%] vs. 10 [3.8%]; odds ratio [OR], 95% confidence interval [CI] {9.40, 3.22-27.46}) and develop PreE (5 [18.5%] vs. 12 [4.5%]; adjusted OR, 95% CI {4.79, 1.55-14.84}). No association was found between EPE(2) and the likelihood for delivery before 37 weeks, 35 weeks, or 32 weeks of gestation. Receiver operating characteristic analysis revealed that EPE(2) level predicted adverse obstetrical outcome (SGA + PreE) with 38.5% and 91.7% sensitivity and specificity, respectively. Using a serum peak E(2) cutoff value of 3,450 pg/mL (>90th percentile level), the positive predictive value was 37%, while the negative predictive value was 92%.
  
  
  CONCLUSIONS
  EPE(2) level (>3,450 pg/mL) on the day of hCG administration during COH is associated with greater odds of developing PreE and delivery of an SGA infant in singleton pregnancies resulting from IVF cycles.
authors.affiliation: Massachusetts General Hospital Fertility Center, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2622, USA. aimudia@partners.org
authors.forename: Anthony N
authors.initials: AN
authors.lastname: Imudia
authors.forename: Awoniyi O
authors.initials: AO
authors.lastname: Awonuga
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Doyle
authors.forename: Anjali J
authors.initials: AJ
authors.lastname: Kaimal
authors.forename: Diane L
authors.initials: DL
authors.lastname: Wright
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Toth
authors.forename: Aaron K
authors.initials: AK
authors.lastname: Styer
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004958:Estradiol / Q000097:blood*; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects / Q000706:statistics & numerical data*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D008297:Male; D010062:Ovulation Induction / Q000009:adverse effects / Q000706:statistics & numerical data*; D010922:Placenta Diseases / Q000097:blood / Q000453:epidemiology; D011225:Pre-Eclampsia / Q000097:blood / Q000453:epidemiology*; D011247:Pregnancy; D047928:Premature Birth / Q000097:blood / Q000453:epidemiology*; D015995:Prevalence; D012102:Reproductive Control Agents / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D006063:Chorionic Gonadotropin; D012102:Reproductive Control Agents; D004958:Estradiol